Knowledge Tree
Relations (1)
related 2.58 — strongly supporting 5 facts
Esketamine is the s-enantiomer of the racemic mixture ketamine [1], and both are clinically utilized for treating mood disorders [2] and treatment-resistant depression {fact:1, fact:4}. They share similar clinical safety profiles regarding long-term side effects [3] and are administered through protocols that involve comparable dosing frequency adjustments [4].
Facts (5)
Sources
The Montreal model: an integrative biomedical-psychedelic ... frontiersin.org 5 facts
claimEsketamine is utilized in clinical protocols that feature gradually less-frequent dosing, similar to the protocols used for intravenous ketamine.
referenceBrendle et al. (2022) analyzed the cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the United States, utilizing clinical trial efficacy and real-world effectiveness estimates.
referenceCeban et al. (2021) reviewed the prevention and management of common adverse effects associated with ketamine and esketamine treatment in patients with mood disorders.
claimIntranasal esketamine, the s-enantiomer of ketamine, is dosed to minimize psychoactive effects and has received regulatory approval in multiple countries for unipolar treatment-resistant depression when used with conventional oral antidepressants.
claimClinical use of ketamine or esketamine has not been associated with iatrogenic dependence, cognitive decline beyond transient memory disruption, or toxic bladder effects.